US Patent

US8263122 — Wet granulation using a water sequestering agent

Formulation · Assigned to Rigel Pharmaceuticals Inc · Expires 2030-11-24 · 5y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a method for preparing tablets of a specific formulation of Fostamatinib disodium using a wet granulation process.

USPTO Abstract

Disclosed are tablets comprising hydrolytically stable formulations of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt (Compound 1) prepared by a wet granulation process.

Drugs covered by this patent

fostamatinib-disodium (FOSTAMATINIB DISODIUM)

Patent Metadata

Patent number: US8263122
Jurisdiction: US
Classification: Formulation
Expires: 2030-11-24
Drug substance claim: No
Drug product claim: Yes
Assignee: Rigel Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.